TXG — 10x Genomics, Inc.

10x Genomics Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $166 million, a 1% increase year-over-year, exceeding guidance.
• Full Year Revenue: $599 million, excluding $44 million from patent litigation settlements.
• Consumables Revenue: Up 6% overall; single-cell consumables grew 3%, while spatial consumables grew 14%.
• Instrument Revenue: Declined 36% overall, with Chromium instruments down 44% and spatial instruments down 30%.
• Gross Margin: Improved to 68% from 67% year-over-year, driven by lower inventory write-downs.
• Operating Expenses: Decreased 18% in Q4, reflecting cost discipline.
• Cash Position: Ended the year with $523 million in cash, up $130 million from 2024.

2. Strategic Updates and Business Highlights

• Product Innovation: Launched Flex Apex, a next-generation single-cell assay, which has quickly become popular among customers. Continued to enhance spatial platforms with new products like Visium HD 3 Prime and Xenium RNA and protein.
• Market Trends: Strong demand for single-cell and spatial technologies, particularly in AI-driven projects and translational research.
• Collaborations: Engaged in partnerships with notable institutions (e.g., Chan Zuckerberg Initiative, Arc Institute) to support large-scale data generation for AI applications.
• Clinical Applications: Initiated efforts to build a CLIA lab for clinical diagnostics, focusing on oncology and autoimmune disease monitoring.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $600 million and $625 million, indicating 0% to 4% growth over 2025.
• Q1 Expectations: Anticipated to represent a larger percentage of full-year revenue due to orders received late in Q4.
• Market Stability: While funding remains constrained, there are signs of stability, particularly with recent NIH budget approvals.

4. Bad News, Challenges, or Points of Concern

• Subdued Customer Spending: Continued challenges in capital equipment purchases and research funding dynamics affecting customer sentiment.
• Instrument Revenue Decline: Significant drop in instrument sales, particularly in the U.S. market, due to funding constraints.
• Competitive Pressures: Concerns about maintaining market share amidst increasing competition in both single-cell and spatial technologies.
• Uncertainty in Academic Funding: Ongoing unpredictability in academic budgets and grant approvals could impact future sales.

5. Notable Q&A Insights

• Customer Sentiment: The current environment remains cautious, with gradual improvement noted compared to the first half of 2025.
• Flex Apex Adoption: Early feedback is positive, with expectations for increased utilization, although the transition from older products may vary.
• Translational Research Focus: Aiming to expand biopharma revenue, with a goal of eventually reaching half of total revenue from this segment.
• AI Integration: Demand for AI-driven projects is growing, with Flex Apex positioned as a key product for these applications.
• Clinical Strategy: Plans for the CLIA lab are in place, with a focus on generating clinical evidence and deploying diagnostics in collaboration with medical institutions.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, challenges, and insights from the Q&A, providing a comprehensive overview of 10x Genomics' performance and outlook.